43 results
PRE 14A
GTHX
G1 Therapeutics Inc
12 Apr 24
Preliminary proxy
4:12pm
the benefit of trilaciclib in reducing ADC-related adverse events, indicated possible long-term survival trends, and will help to inform future development … is committed to maintaining sound corporate governance practices and creating long-term stockholder value. We highlight some of our corporate governance
8-K
EX-99.1
zqja79d 3jgogep2
28 Feb 24
Results of Operations and Financial Condition
6:35am
8-K
EX-99.1
3aqjs lf9lv2ccmp
8 Jan 24
Results of Operations and Financial Condition
6:30am
8-K
EX-99.1
q3zuvpvut agu
2 Aug 23
Results of Operations and Financial Condition
6:50am
8-K
EX-1.1
hrnec4suxmxw1t7jvzu
18 Nov 22
G1 Therapeutics Announces Pricing of Offering of Common Stock
8:00pm
424B5
tu066a
18 Nov 22
Prospectus supplement for primary offering
7:37pm
424B5
t6spgmbn
17 Nov 22
Prospectus supplement for primary offering
4:04pm
8-K
EX-99.1
8naiixdwet1g9ei52r
2 Nov 22
G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights
6:45am